Olmesafe-HT
Generic Name
Olmesartan Medoxomil and Hydrochlorothiazide
Manufacturer
Square Pharmaceuticals Ltd.
Country
Bangladesh
Loading images...
Price Details
Current market pricing information
| Variant | Unit Price | Strip Price |
|---|---|---|
| olmesafe ht 20 mg tablet | ৳ 8.00 | ৳ 80.00 |
Description
Overview of the medicine
Olmesafe-HT 20 mg Tablet is a combination medicine used to treat essential hypertension (high blood pressure) in adult patients whose blood pressure is not adequately controlled on olmesartan medoxomil or hydrochlorothiazide alone. It contains Olmesartan, an angiotensin II receptor blocker (ARB), and Hydrochlorothiazide, a thiazide diuretic, which work synergistically to lower blood pressure.
Uses & Indications
Dosage
Adults
Usually one tablet (Olmesartan 20 mg/HCTZ 12.5 mg) once daily. Dosage may be titrated based on blood pressure response.
Elderly
No initial dose adjustment is generally required, but caution is advised. Monitor renal function.
Renal_impairment
Not recommended for patients with severe renal impairment (creatinine clearance <30 mL/min). Moderate impairment requires caution and monitoring.
How to Take
Take orally once daily with or without food. Swallow the tablet whole with water. It is advisable to take it at the same time each day, preferably in the morning.
Mechanism of Action
Olmesartan selectively blocks the binding of angiotensin II to the AT1 receptor, inhibiting its vasoconstrictive and aldosterone-secreting effects, thereby lowering blood pressure. Hydrochlorothiazide increases the excretion of sodium and chloride by inhibiting their reabsorption in the distal convoluted tubule, leading to increased urine output and reduced blood volume, which contributes to blood pressure reduction.
Pharmacokinetics
Onset
Antihypertensive effect observed within 1 week, maximal effect usually within 2-4 weeks.
Excretion
Olmesartan: Primarily excreted unchanged in bile (50-65%) and urine (35-50%). Hydrochlorothiazide: Excreted mostly unchanged by the kidneys.
Half life
Olmesartan: Approximately 13 hours. Hydrochlorothiazide: Approximately 5.8-14.8 hours.
Absorption
Olmesartan: Bioavailability is approximately 26%. Food does not affect its absorption. Cmax is reached within 1-2 hours. Hydrochlorothiazide: Bioavailability is 65-75%. Cmax is reached within 1-2.5 hours.
Metabolism
Olmesartan: No significant metabolism by cytochrome P450 system. Hydrochlorothiazide: Not metabolized.
Side Effects
Contraindications
- Hypersensitivity to Olmesartan, Hydrochlorothiazide, or sulfonamide-derived drugs.
- Anuria.
- Severe renal impairment (creatinine clearance <30 mL/min).
- Severe hepatic impairment.
- Pregnancy (especially second and third trimesters).
- Concomitant use with aliskiren in patients with diabetes or renal impairment.
Drug Interactions
Lithium
Increased serum lithium concentrations and lithium toxicity. Monitor lithium levels.
Other Antihypertensives
Additive hypotensive effect.
Alcohol, Barbiturates, or Narcotics
Potentiation of orthostatic hypotension.
Colestyramine and Colestipol resins
May impair absorption of HCTZ.
NSAIDs (Nonsteroidal Anti-inflammatory Drugs)
May reduce the antihypertensive effect of Olmesartan and HCTZ; may worsen renal function in susceptible patients.
Potassium-sparing diuretics/Potassium supplements
May lead to hyperkalemia.
Storage
Store in a cool, dry place below 30°C. Protect from light and moisture. Keep out of reach of children.
Overdose
Symptoms: Hypotension, tachycardia, bradycardia (less common), dehydration, electrolyte imbalance. Management: Symptomatic and supportive treatment. Induce vomiting or perform gastric lavage. Administer activated charcoal. Correct fluid and electrolyte imbalances. Closely monitor vital signs.
Pregnancy & Lactation
Pregnancy: Category D (2nd and 3rd trimesters). Discontinue immediately if pregnancy is detected. Lactation: Not recommended. Both Olmesartan and HCTZ are excreted in breast milk.
Side Effects
Contraindications
- Hypersensitivity to Olmesartan, Hydrochlorothiazide, or sulfonamide-derived drugs.
- Anuria.
- Severe renal impairment (creatinine clearance <30 mL/min).
- Severe hepatic impairment.
- Pregnancy (especially second and third trimesters).
- Concomitant use with aliskiren in patients with diabetes or renal impairment.
Drug Interactions
Lithium
Increased serum lithium concentrations and lithium toxicity. Monitor lithium levels.
Other Antihypertensives
Additive hypotensive effect.
Alcohol, Barbiturates, or Narcotics
Potentiation of orthostatic hypotension.
Colestyramine and Colestipol resins
May impair absorption of HCTZ.
NSAIDs (Nonsteroidal Anti-inflammatory Drugs)
May reduce the antihypertensive effect of Olmesartan and HCTZ; may worsen renal function in susceptible patients.
Potassium-sparing diuretics/Potassium supplements
May lead to hyperkalemia.
Storage
Store in a cool, dry place below 30°C. Protect from light and moisture. Keep out of reach of children.
Overdose
Symptoms: Hypotension, tachycardia, bradycardia (less common), dehydration, electrolyte imbalance. Management: Symptomatic and supportive treatment. Induce vomiting or perform gastric lavage. Administer activated charcoal. Correct fluid and electrolyte imbalances. Closely monitor vital signs.
Pregnancy & Lactation
Pregnancy: Category D (2nd and 3rd trimesters). Discontinue immediately if pregnancy is detected. Lactation: Not recommended. Both Olmesartan and HCTZ are excreted in breast milk.
Frequently Asked Questions
Common questions about this medicine
Pack Sizes
Shelf Life
Typically 24-36 months from manufacturing date
Availability
Pharmacies, Hospitals
Approval Status
Approved by national health authorities
Patent Status
Generic available (Patent expired for main components)
Clinical Trials
Extensive clinical trials have demonstrated the efficacy and safety of Olmesartan/HCTZ combination in reducing blood pressure and cardiovascular events in hypertensive patients.
Lab Monitoring
- Blood pressure monitoring
- Serum electrolytes (Potassium, Sodium)
- Renal function (BUN, Creatinine)
- Liver function tests
- Serum uric acid
- Blood glucose
Doctor Notes
- Regular monitoring of blood pressure, renal function, and electrolytes is crucial.
- Advise patients on lifestyle modifications.
- Caution in patients with severe aortic stenosis or hypertrophic obstructive cardiomyopathy.
- Diuretic effect of HCTZ may lead to dehydration, especially in elderly or those with heart failure.
Patient Guidelines
- Take this medicine regularly as directed by your doctor, even if you feel well.
- Do not stop taking it suddenly without consulting your doctor.
- Avoid using potassium supplements or salt substitutes containing potassium without medical advice.
- Inform your doctor about all other medications you are taking.
Missed Dose Advice
If you miss a dose, take it as soon as you remember. If it is almost time for your next dose, skip the missed dose and resume your regular dosing schedule. Do not double the dose.
Driving Precautions
This medicine may cause dizziness or fatigue. If you experience these symptoms, avoid driving or operating machinery until you know how it affects you.
Lifestyle Advice
- Adopt a healthy lifestyle including a balanced diet low in sodium and saturated fats.
- Engage in regular physical activity.
- Maintain a healthy weight.
- Limit alcohol intake.
- Quit smoking.
Alternative Medicines in Bangladesh
Similar medicines available in the market
Global Brand Names
International brand names for this medicine. Click a brand to search for detailed information.